JP2006516616A - 即効薬剤組成物 - Google Patents

即効薬剤組成物 Download PDF

Info

Publication number
JP2006516616A
JP2006516616A JP2006502771A JP2006502771A JP2006516616A JP 2006516616 A JP2006516616 A JP 2006516616A JP 2006502771 A JP2006502771 A JP 2006502771A JP 2006502771 A JP2006502771 A JP 2006502771A JP 2006516616 A JP2006516616 A JP 2006516616A
Authority
JP
Japan
Prior art keywords
composition
composition according
carrier particles
sublingual
bio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006502771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516616A5 (enExample
Inventor
クリステル・ニストレーム
スザンヌ・ブレデンベルグ
Original Assignee
オレクソ・アクチエボラゲット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オレクソ・アクチエボラゲット filed Critical オレクソ・アクチエボラゲット
Publication of JP2006516616A publication Critical patent/JP2006516616A/ja
Publication of JP2006516616A5 publication Critical patent/JP2006516616A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006502771A 2003-01-31 2004-01-15 即効薬剤組成物 Pending JP2006516616A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44385703P 2003-01-31 2003-01-31
PCT/SE2004/000037 WO2004067004A1 (en) 2003-01-31 2004-01-15 A rapid-acting pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2006516616A true JP2006516616A (ja) 2006-07-06
JP2006516616A5 JP2006516616A5 (enExample) 2011-01-13

Family

ID=32825385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502771A Pending JP2006516616A (ja) 2003-01-31 2004-01-15 即効薬剤組成物

Country Status (20)

Country Link
US (2) US20060216352A1 (enExample)
EP (1) EP1587514B3 (enExample)
JP (1) JP2006516616A (enExample)
KR (1) KR20050096950A (enExample)
CN (1) CN100581586C (enExample)
AT (1) ATE329594T1 (enExample)
AU (1) AU2004208644B2 (enExample)
CA (1) CA2512559A1 (enExample)
CY (1) CY1106154T1 (enExample)
DE (1) DE602004001209T3 (enExample)
DK (1) DK1587514T3 (enExample)
ES (1) ES2270335T7 (enExample)
MX (1) MXPA05008140A (enExample)
NO (1) NO20053277L (enExample)
NZ (1) NZ541167A (enExample)
PL (1) PL211224B1 (enExample)
PT (1) PT1587514E (enExample)
RU (1) RU2345791C2 (enExample)
SI (1) SI1587514T1 (enExample)
WO (1) WO2004067004A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521433A (ja) * 2005-12-23 2009-06-04 ステンバーグ，カージェル 低粘度アルギン酸塩含有水溶性薄膜
JP2010531153A (ja) * 2007-01-05 2010-09-24 エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド 経粘膜剤形の投与のための貯蔵および投与デバイス
JP2012504155A (ja) * 2008-09-30 2012-02-16 レツク・フアーマシユーテイカルズ・デー・デー エゼチミブを含む配合物
JP2013506683A (ja) * 2009-10-01 2013-02-28 アプタリス ファーマテク，インコーポレイテッド 経口投与型コルチコステロイド組成物
JP2016510742A (ja) * 2013-03-04 2016-04-11 ベザン ヘルスケア ルクセンブルク エスエーアールエルＢｅｓｉｎｓ Ｈｅａｌｔｈｃａｒｅ Ｌｕｘｅｍｂｏｕｒｇ Ｓａｒｌ 担体粒子に結合した活性物質ナノ粒子を含む乾燥医薬組成物
JP2018021000A (ja) * 2015-09-11 2018-02-08 シムライズ アーゲー 経口投与剤形
US10105315B2 (en) 2016-08-18 2018-10-23 Adare Pharmaceuticals, Inc. Methods of treating eosinophilic esophagitis
US10471071B2 (en) 2013-09-06 2019-11-12 Adare Pharmaceuticals, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
KR101184138B1 (ko) 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
NZ548215A (en) 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
KR20070030178A (ko) * 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
AU2006228296B2 (en) * 2005-03-28 2011-08-04 Orexo Ab New pharmaceutical compositions useful in the treatment of Parkinson's disease
EP1863456A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of pain
BRPI0609984A2 (pt) * 2005-05-25 2010-05-18 Transcept Pharmaceuticals Inc uso de zolpidem ou um sal do mesmo
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) * 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
WO2008067549A2 (en) * 2006-11-30 2008-06-05 Transcept Pharmaceuticals, Inc. Stabilized zolpidem pharmaceutical compositions
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010107761A1 (en) 2009-03-18 2010-09-23 Acelrx Pharmaceuticals, Inc. Improved storage and dispensing devices for administration of oral transmucosal dosage forms
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) * 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
WO2011053251A1 (en) 2009-10-30 2011-05-05 Ix Biopharma Pte Ltd Fast dissolving solid dosage form
WO2011087705A2 (en) 2009-12-22 2011-07-21 Fmc Corporation Fine particle croscarmellose and uses thereof
WO2012106058A2 (en) 2011-01-31 2012-08-09 New Market Pharmaceuticals Animal treatments
ME02153B (me) 2011-09-19 2015-10-20 Orexo Ab Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida
EP3505159B1 (en) 2012-05-02 2020-11-04 NewMarket Pharmaceuticals LLC Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
HRP20161634T1 (hr) 2012-05-02 2017-01-13 Orexo Ab Novi pripravak alfentanila za liječenje akutne boli
BR112017013311B1 (pt) 2014-12-23 2022-05-31 Acelrx Pharmaceuticals, Inc Aparelho para a dispensação de formas de dosagem via oral e transmucosal
CN105147721A (zh) * 2015-08-28 2015-12-16 施康培医疗科技（武汉）有限公司 一种抑菌清洗剂及其使用方法
CN106822007B (zh) * 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂
CA3010636A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
TW202210072A (zh) 2020-05-26 2022-03-16 美商羅德科技公司 用於鼻內或吸入遞送之大麻素組合物及劑型
IT202100010802A1 (it) * 2021-05-03 2022-11-03 Alfasigma Spa Formulazione solida mucoadesiva comprendente probiotici per uso nella prevenzione e nel trattamento di disbiosi orale.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324725A1 (en) * 1988-01-13 1989-07-19 Kabi Pharmacia AB A pharmaceutical composition
JPH1059841A (ja) * 1996-02-27 1998-03-03 Teijin Ltd 吸収性が改善された粉末状経鼻投与組成物
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ
WO2001052894A2 (en) * 2000-01-20 2001-07-26 Basilea Pharmaceutica Ag Nasally administrable cyclic peptide compositions
WO2002047688A2 (en) * 2000-12-11 2002-06-20 Cephalon, Inc. Method and apparatus for treating breakthrough pain
JP2002526439A (ja) * 1998-09-24 2002-08-20 ダイアバクト・エイ・ビー 急性疾患の処置のための製薬学的組成物
JP2002526440A (ja) * 1998-09-24 2002-08-20 ダイアバクト・エイ・ビー 急性疼痛の処置のためのフェンタニル組成物
JP2004043479A (ja) * 2002-07-11 2004-02-12 Taiho Yakuhin Kogyo Kk 経鼻吸収用組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6391452B1 (en) * 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0324725A1 (en) * 1988-01-13 1989-07-19 Kabi Pharmacia AB A pharmaceutical composition
JPH1059841A (ja) * 1996-02-27 1998-03-03 Teijin Ltd 吸収性が改善された粉末状経鼻投与組成物
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ
JP2002526439A (ja) * 1998-09-24 2002-08-20 ダイアバクト・エイ・ビー 急性疾患の処置のための製薬学的組成物
JP2002526440A (ja) * 1998-09-24 2002-08-20 ダイアバクト・エイ・ビー 急性疼痛の処置のためのフェンタニル組成物
WO2001052894A2 (en) * 2000-01-20 2001-07-26 Basilea Pharmaceutica Ag Nasally administrable cyclic peptide compositions
WO2002047688A2 (en) * 2000-12-11 2002-06-20 Cephalon, Inc. Method and apparatus for treating breakthrough pain
JP2004043479A (ja) * 2002-07-11 2004-02-12 Taiho Yakuhin Kogyo Kk 経鼻吸収用組成物

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759282B2 (en) 2005-12-23 2014-06-24 Uppsalagruppen Medical Ab Water-soluble films comprising low-viscosity alginates
JP2009521433A (ja) * 2005-12-23 2009-06-04 ステンバーグ，カージェル 低粘度アルギン酸塩含有水溶性薄膜
JP2010531153A (ja) * 2007-01-05 2010-09-24 エーセルアールエックス ファーマシューティカルズ， インコーポレイテッド 経粘膜剤形の投与のための貯蔵および投与デバイス
JP2012504155A (ja) * 2008-09-30 2012-02-16 レツク・フアーマシユーテイカルズ・デー・デー エゼチミブを含む配合物
JP2022078275A (ja) * 2009-10-01 2022-05-24 アデア ファーマスーティカルズ，インコーポレイテッド 経口投与型コルチコステロイド組成物
US11246828B2 (en) 2009-10-01 2022-02-15 Ellodi Pharmaceuticals, L.P. Orally administered corticosteroid compositions
US9486407B2 (en) 2009-10-01 2016-11-08 Adare Pharmaceuticals, Inc. Orally administered corticosteroid compositions
JP2017036306A (ja) * 2009-10-01 2017-02-16 アデア ファーマスーティカルズ，インコーポレイテッド 経口投与型コルチコステロイド組成物
US9849084B2 (en) 2009-10-01 2017-12-26 Adare Pharmaceuticals, Inc. Orally administered corticosteroid compositions
US12290598B2 (en) 2009-10-01 2025-05-06 Ellodi Pharmaceuticals, L.P. Orally administered corticosteroid compositions
JP2023166486A (ja) * 2009-10-01 2023-11-21 アデア ファーマスーティカルズ，インコーポレイテッド 経口投与型コルチコステロイド組成物
US10632069B2 (en) 2009-10-01 2020-04-28 Adare Pharmaceuticals Us, L.P. Orally administered corticosteroid compositions
JP2013506683A (ja) * 2009-10-01 2013-02-28 アプタリス ファーマテク，インコーポレイテッド 経口投与型コルチコステロイド組成物
US11266598B2 (en) 2009-10-01 2022-03-08 Ellodi Pharmaceuticals, L.P. Orally administered corticosteroid compositions
JP2016510742A (ja) * 2013-03-04 2016-04-11 ベザン ヘルスケア ルクセンブルク エスエーアールエルＢｅｓｉｎｓ Ｈｅａｌｔｈｃａｒｅ Ｌｕｘｅｍｂｏｕｒｇ Ｓａｒｌ 担体粒子に結合した活性物質ナノ粒子を含む乾燥医薬組成物
US10695295B2 (en) 2013-03-04 2020-06-30 Besins Healthcare Luxembourg Sarl Spray-dried pharmaceutical compositions comprising active agent nanoparticles
US10918601B2 (en) 2013-03-04 2021-02-16 Besins Healthcare Luxembourg Sarl Spray-dried pharmaceutical compositions comprising active agent nanoparticles
US10471071B2 (en) 2013-09-06 2019-11-12 Adare Pharmaceuticals, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US11260061B2 (en) 2013-09-06 2022-03-01 Ellodi Pharmaceuticals, L.P. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US11166961B2 (en) 2013-09-06 2021-11-09 Ellodi Pharmaceuticals, L.P. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US12310976B2 (en) 2013-09-06 2025-05-27 Ellodi Pharmaceuticals, L.P. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
US12447157B2 (en) 2013-09-06 2025-10-21 Ellodi Pharmaceuticals, L.P. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP7017849B2 (ja) 2015-09-11 2022-02-09 シムライズ アーゲー 経口投与剤形
JP2018021000A (ja) * 2015-09-11 2018-02-08 シムライズ アーゲー 経口投与剤形
US11026887B2 (en) 2016-08-18 2021-06-08 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis
US11684571B2 (en) 2016-08-18 2023-06-27 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis
US10105315B2 (en) 2016-08-18 2018-10-23 Adare Pharmaceuticals, Inc. Methods of treating eosinophilic esophagitis
US11896710B2 (en) 2016-08-18 2024-02-13 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis
US12059494B2 (en) 2016-08-18 2024-08-13 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis
US12691128B2 (en) 2019-10-01 2026-07-28 Ellodi Pharmaceuticals, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis

Also Published As

Publication number Publication date
ES2270335T7 (es) 2012-03-16
KR20050096950A (ko) 2005-10-06
DK1587514T3 (da) 2006-10-16
DE602004001209D1 (de) 2011-01-05
CN1744898A (zh) 2006-03-08
WO2004067004A1 (en) 2004-08-12
PL378051A1 (pl) 2006-02-20
CA2512559A1 (en) 2004-08-12
DE602004001209T2 (de) 2007-04-26
ES2270335T3 (es) 2007-04-01
EP1587514A1 (en) 2005-10-26
EP1587514B3 (en) 2011-06-22
US20060216352A1 (en) 2006-09-28
RU2005127353A (ru) 2006-06-10
NZ541167A (en) 2008-07-31
MXPA05008140A (es) 2005-09-30
US20110256229A1 (en) 2011-10-20
HK1080387A1 (en) 2006-04-28
RU2345791C2 (ru) 2009-02-10
ATE329594T1 (de) 2006-07-15
AU2004208644A1 (en) 2004-08-12
CY1106154T1 (el) 2011-06-08
SI1587514T1 (sl) 2006-10-31
PL211224B1 (pl) 2012-04-30
NO20053277L (no) 2005-07-15
PT1587514E (pt) 2006-09-29
EP1587514B1 (en) 2006-06-14
AU2004208644B2 (en) 2009-07-23
CN100581586C (zh) 2010-01-20
DE602004001209T3 (de) 2012-03-15
NO20053277D0 (no) 2005-07-05

Similar Documents

Publication Publication Date Title
AU2004208644B2 (en) A rapid-acting pharmaceutical composition
JP2006516616A5 (enExample)
EP1652518B1 (en) Pharmaceutical composition for sublingual administration
HK1080387B (en) A rapid-acting pharmaceutical composition
HK1148458B (en) Pharmaceutical composition comprising fentanyl for the treatment of acute or breakthrough pain by sublingual administration
HK1091722B (en) Pharmaceutical composition for sublingual administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100811

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120110